We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+15.97%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$119M
AUM Growth
-$29.2M
Cap. Flow
-$43.3M
Cap. Flow %
-36.49%
Top 10 Hldgs %
54.42%
Holding
88
New
24
Increased
10
Reduced
14
Closed
37

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.54M
2
CEMP
Cempra, Inc.
CEMP
+$5.12M
3
ASND icon
Ascendis Pharma A/S
ASND
+$4.16M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$3.02M
5
FOLD
Amicus Therapeutics
FOLD
+$2.93M

Top Sells

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$2.97M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$2.9M
3
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$2.74M
4
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$2.42M
5
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$2.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.05%
2 Consumer Discretionary 2.48%
3 Industrials 0.85%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INNL
26
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$1.31M 1.1%
164,459
+351
+0.2% +$2.76K
OCGN icon
27
Ocugen
OCGN
$423M
$1.23M 1.04%
2,054
-226
-10% -$130K
CRDC
28
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.15M 0.97%
181,944
+35,353
+24% +$217K
BLCM
29
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.02M 0.86%
4,399
-176
-4% -$42.6K
EGOV
30
DELISTED
NIC Inc
EGOV
$1.01M 0.85%
+57,143
New +$972K
RXDX
31
DELISTED
Ignyta, Inc.
RXDX
$995K 0.84%
100,000
-269,360
-73% -$2.02M
NXTM
32
DELISTED
NxStage Medical Inc.
NXTM
$928K 0.78%
+53,665
New +$948K
SRNE
33
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$925K 0.78%
+80,000
New +$926K
AVEO
34
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$861K 0.73%
+59,387
New +$649K
EXEL icon
35
CALL
Exelixis
EXEL
$13.8B
$846K 0.71%
+329,000
New +$764K
DYAX
36
CALL
DELISTED
DYAX CORPORATION
DYAX
$838K 0.71%
+50,000
New +$778K
AGRX
37
DELISTED
Agile Therapeutics
AGRX
$750K 0.63%
+40
New +$701K
OTIC
38
DELISTED
Otonomy, Inc.
OTIC
$707K 0.6%
+20,000
New +$684K
CEMI
39
DELISTED
Chembio diagnostics, Inc.
CEMI
$590K 0.5%
146,099
– –
MOLG
40
DELISTED
MOL GLOBAL INC SPONSORED ADR
MOLG
$563K 0.47%
246,009
-93,566
-28% -$219K
KIN
41
DELISTED
Kindred Biosciences, Inc.
KIN
$536K 0.45%
75,000
-96,807
-56% -$667K
WINT
42
DELISTED
Windtree Therapeutics Inc
WINT
$468K 0.39%
+28,082
New +$553K
GNVC
43
DELISTED
GenVec, Inc.
GNVC
$456K 0.38%
15,451
-20,027
-56% -$658K
CERS icon
44
Cerus
CERS
$433M
$417K 0.35%
100,000
-208,282
-68% -$1.07M
SMLR
45
DELISTED
Semler Scientific
SMLR
$403K 0.34%
+115,148
New +$458K
SAGE
46
DELISTED
Sage Therapeutics
SAGE
$402K 0.34%
+8,000
New +$344K
MRNS
47
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$325K 0.27%
+9,027
New +$396K
ZSAN
48
DELISTED
Zosano Pharma Corporation
ZSAN
$222K 0.19%
+31
New +$233K
ANGO icon
49
AngioDynamics
ANGO
$627M
$178K 0.15%
+10,000
New +$186K
TXMD icon
50
TherapeuticsMD
TXMD
$23.6M
$114K 0.1%
+378
New +$92.3K
1
2
3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2015 Portfolio in Review

As of Q1 2015, Acuta Capital Partners held 88 positions worth $119M, down 20% from $148M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Acuta Capital Partners withdrew a net $43.3M in Q1 2015, closing 37 positions and reducing 14 holdings. Its most notable exit was Tetraphase Pharmaceuticals, Inc., an estimated $2.97M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 48% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Acuta Capital Partners opened a new position in Iovance Biotherapeutics worth $8.1M.

  • Acuta Capital Partners's largest Q1 2015 buy was Iovance Biotherapeutics: 669,196 shares worth $8.1M.
  • Acuta Capital Partners added most to Amicus Therapeutics in Q1 2015, an estimated $2.93M increase.
  • Acuta Capital Partners's biggest Q1 2015 reduction was Pernix Therapeutics Holdings, Inc., cutting an estimated $2.42M.
  • Acuta Capital Partners fully exited Tetraphase Pharmaceuticals, Inc. in Q1 2015, selling an estimated $2.97M.
  • Acuta Capital Partners's ten largest holdings make up 54% of its $119M portfolio in Q1 2015.
  • Acuta Capital Partners opened 24 new positions and closed 37 in Q1 2015.
  • Acuta Capital Partners's portfolio value fell 20% quarter-over-quarter to $119M.

Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.